New drug may protect against memory loss in Alzheimer’s disease

A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer’s disease. Preclinical research found that the drug—called BPN14770—deters the effects of amyloid beta, a hallmark protein of Alzheimer’s that is toxic to Continue Reading

Progress in understanding Alzheimer’s disease genetics, hope remains for drugs in testing

What is happening with Alzheimer’s disease research and treatment? We heard from Maria Carrillo, chief science officer of the nationwide Alzheimer’s Association, during a recent visit to San Diego. Here are some questions and answers from the interview, edited for space and clarity. Q: There have been several failed clinical Continue Reading

Alzheimer’s research increasingly focused on links to sleep and other behaviors

Sleep and other behavioral topics are growing within Alzheimer’s disease research, according to a new report released today by Elsevier, a global information analytics business specializing in science and health. To coincide with World Alzheimer’s Month, Elsevier analyzed Alzheimer’s research published since the 1970s offering a comprehensive view of the Continue Reading

Creation of new brain cells plays an underappreciated role in Alzheimer’s disease

Much of the research on the underlying causes of Alzheimer’s disease focuses on amyloid beta (Aß), a protein that accumulates in the brain as the disease progresses. Excess Aß proteins form clumps or “plaques” that disrupt communication between brain cells and trigger inflammation, eventually leading to widespread loss of neurons Continue Reading

Carriers of Alzheimer’s genetic marker have greater difficulty harnessing past knowledge

Adults carrying a gene associated with a higher risk of Alzheimer’s disease had a harder time accessing recently acquired knowledge, even though they didn’t show any symptoms of memory problems, according to findings published in a joint Baycrest-University of Oxford study. Researchers found that older adults carrying a specific strain Continue Reading

Alzheimer’s drug reverses brain damage from adolescent alcohol exposure in rats

A drug used to slow cognitive decline in adults with Alzheimer’s disease appears to reverse brain inflammation and neuron damage in rats exposed to alcohol during adolescence. In a study described in the journal Scientific Reports, Duke Health researchers sought to understand how intermittent binge drinking changes the hippocampus—a region Continue Reading

Using math to help treat Alzheimer’s, Parkinson’s and other diseases

Protein aggregation—in which misfolded proteins clump together to form large fibrils—has been implicated in many diseases including Alzheimer’s, Parkinson’s, and type II diabetes. While the exact role these fibrils play in diseases isn’t fully understood, many of the current treatments for diseases like Alzheimer’s and Parkinson’s target the aggregation process. Continue Reading

Alzheimer’s disease destroys neurons that keep us awake

Researchers and caregivers have noted that excessive daytime napping can develop long before the memory problems associated with Alzheimer’s disease begin to unfold. Prior studies have considered this excessive daytime napping to be compensation for poor nighttime sleep caused by Alzheimer’s-related disruptions in sleep-promoting brain regions, while others have argued Continue Reading

Researchers first to map structure of protein aggregate that leads to Alzheimer’s

A research team including faculty at Binghamton University and University of Colorado Denver are the first to map the molecular structure of an aggressive protein aggregate that causes acceleration of Alzheimer’s disease. “Approximately 10 percent of Alzheimer’s cases result from familial mutations,” said Wei Qiang, assistant professor of biophysical chemistry Continue Reading

Depression symptoms in Alzheimer’s could be signs for cognitive decline

BOSTON -Increasingly, Alzheimer’s disease (AD) research has focused on the preclinical stage, when people have biological evidence of AD but no or minimal symptoms, and when interventions might have the potential to prevent future decline of older adults. Researchers from Massachusetts General Hospital (MGH) have shed important new light on Continue Reading